OBJECTIVE: To determine serum interleukin 9 (IL-9) levels and their clinical associations in patients with systemic sclerosis (SSc). METHODS: Serum IL-9 levels were examined by ELISA in 71 patients with SSc, 15 with systemic lupus erythematosus (SLE), 15 with dermatomyositis (DM), 39 with atopic dermatitis, and 28 healthy individuals. RESULTS: Serum IL-9 levels were significantly elevated in SSc patients (84.6 ± 76.0 pg/ml) compared with healthy individuals (40.4 ± 41.7 pg/ml; p < 0.001), and patients with SLE (50.7 ± 52.0 pg/ml; p < 0.05) or DM (50.6 ± 55.8 pg/ml; p < 0.05) or atopic dermatitis (41.8 ± 38.8 pg/ml; p < 0.001). Among SSc patients, there were no differences in serum IL-9 levels between those with limited cutaneous SSc and those with diffuse cutaneous SSc. Patients with SSc and raised IL-9 levels less often had pulmonary fibrosis and decreased percentage vital capacity than those with normal IL-9 levels. IL-9 levels were positively correlated with percentage vital capacity in patients with SSc. CONCLUSION: Serum IL-9 level was increased in patients with SSc, and was associated with lower frequency and severity of pulmonary fibrosis in SSc. IL-9 could be a protective factor against the development of pulmonary fibrosis in this disease, and as such would be a possible therapeutic target.
OBJECTIVE: To determine serum interleukin 9 (IL-9) levels and their clinical associations in patients with systemic sclerosis (SSc). METHODS: Serum IL-9 levels were examined by ELISA in 71 patients with SSc, 15 with systemic lupus erythematosus (SLE), 15 with dermatomyositis (DM), 39 with atopic dermatitis, and 28 healthy individuals. RESULTS: Serum IL-9 levels were significantly elevated in SSc patients (84.6 ± 76.0 pg/ml) compared with healthy individuals (40.4 ± 41.7 pg/ml; p < 0.001), and patients with SLE (50.7 ± 52.0 pg/ml; p < 0.05) or DM (50.6 ± 55.8 pg/ml; p < 0.05) or atopic dermatitis (41.8 ± 38.8 pg/ml; p < 0.001). Among SSc patients, there were no differences in serum IL-9 levels between those with limited cutaneous SSc and those with diffuse cutaneous SSc. Patients with SSc and raised IL-9 levels less often had pulmonary fibrosis and decreased percentage vital capacity than those with normal IL-9 levels. IL-9 levels were positively correlated with percentage vital capacity in patients with SSc. CONCLUSION: Serum IL-9 level was increased in patients with SSc, and was associated with lower frequency and severity of pulmonary fibrosis in SSc. IL-9 could be a protective factor against the development of pulmonary fibrosis in this disease, and as such would be a possible therapeutic target.
Authors: G Guggino; M Lo Pizzo; D Di Liberto; A Rizzo; P Cipriani; P Ruscitti; G Candore; C M Gambino; G Sireci; F Dieli; R Giacomelli; G Triolo; F Ciccia Journal: Clin Exp Immunol Date: 2017-08-23 Impact factor: 4.330
Authors: Ida Gregersen; Mona Skjelland; Sverre Holm; Kirsten B Holven; Kirsten Krogh-Sørensen; David Russell; Erik T Askevold; Christen P Dahl; Stein Ørn; Lars Gullestad; Tom E Mollnes; Thor Ueland; Pål Aukrust; Bente Halvorsen Journal: PLoS One Date: 2013-08-30 Impact factor: 3.240